Cardiac coherence
OtherUse of Cardiac coherence (complementary respiratory training) during 6 month
NCT Number: NCT05851859
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.
The Reunion Island is a French overseas department located in the Indian Ocean accounting more than 860,000 inhabitants. It has recorded since March 11, 2020, nearly 491,825 cases of COVID-19 and 961 deaths of hospitalized patients. Reunion's population is multi-ethnic and younger than the metropolitan France's one. It also has a higher prevalence of obesity and type 2 diabetes, two serious form factors of COVID-19. This specific context makes this island a particular study site for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Long COVID.
In addition, some studies have confirmed the involvement of the autonomic nervous system (ANS) in the symptomatology of Long COVID and demonstrated that patients with a Long COVID present a dysfunction of their ANS which is objectified by a reduced Heart Rate Variability (HRV). The regulation of heart rate by the ANS is strongly favored by respiration. A regular slow and deep breathing training helps to adjust the baroreflex, which connect heart rate, breathing and blood pressure. The result of this training is an induced state called "cardiac coherence" (CC).
The investigator therefore hypothesize that respiratory training to CC could "re-educate" the ANS and durably improve the symptomatology of patients with Long COVID.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
CHU de la Réunion, Saint-Denis, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients:
Use of Cardiac coherence (complementary respiratory training) during 6 month
Time frame: 6 months
mean score on the Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome
Time frame: T0, 1 month, 2 months, 3 months, 6 months
Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome
Time frame: 3 months, 6 months
The 11-item Chalder Fatigue Scale (CFS-11) score 0 to 11 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Modified Medical Research Council (MMRC) dyspnoea scale score 0 to 5 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Hospital Anxiety and Depression scale (HADS) Score 0 to 42 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Montreal Cognitive Assessment (MoCA) Score 0 to 30 / Higher score mean better outcome
Time frame: 3 months, 6 months
Posttraumatic Stress Disorder Checklist for Diagnostic and statistical manual of mental disorders, version 5 (PCL-5) Score 0 to 80 / Higher score mean worse outcome
Time frame: T0, 1 month, 2 months, 3 months, 6 months
Long COVID Impact Tool (IT) scale Score 0 to 60 / Higher score mean worse outcome
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de la Réunion
Other
Randomized Controlled Trial Evaluating the Effectiveness of a Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital
Acronym: COCO-Long'Run
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06928116
Body Temperature Changes, COVID-19
Omaha, Nebraska, United States
View Trial DetailsNCT06940609
COVID-19, Chronic Disease
Albuquerque, New Mexico, United States
View Trial DetailsNCT07224490
COVID-19, Chronic Disease
Boston, Massachusetts, United States
View Trial DetailsNCT06920628
COVID-19, Chronic Disease
Bethesda, Maryland, United States
View Trial Details